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Abstract
Motivation: Genome-wide association studies are identifying single nucleotide variants (SNVs) linked to
various diseases, however the functional effect caused by these variants is often unknown. One potential
functional effect, the loss or gain of protein phosphorylation sites, can be induced through variations in
key amino acids that disrupt or introduce valid kinase binding patterns. Current methods for predicting the
effect of SNVs on phosphorylation operate on the sequence content of reference and variant proteins.
However, consideration of the amino acid sequence alone is insufficient for predicting phosphorylation
change, as context factors determine kinase-substrate selection.
Results:We present here a method for quantifying the effect of SNVs on protein phosphorylation through
an integrated system of motif analysis and context-based assessment of kinase targets. By predicting
the effect that known variants across the proteome have on phosphorylation, we are able to use this
background of proteome-wide variant effects to quantify the significance of novel variants for modifying
phosphorylation. We validate our method on a manually curated set of phosphorylation change-causing
variants from the primary literature, showing that the method predicts known examples of phosphorylation
change at high levels of specificity. We apply our approach to data-sets of variants in phosphorylation
site regions, showing that variants causing predicted phosphorylation loss are over-represented among
disease-associated variants.
Availability: The method is freely available as a web-service at the website http://bioinf.scmb.uq.
edu.au/phosphopick/snp
Contact: m.boden@uq.edu.au
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The identification of genetic variants linked to disease is transforming the
biomedical research landscape. Genomewide association studies (GWAS)
have been identifying numerous single nucleotide variants (SNVs) over-
represented in patients within a wide variety of diseases including cancer.
While many SNVs are being discovered, the precise effect that they have
on resultant RNA or protein products is generally not known. One of the
potential effects of non-synonymous SNVs (nsSNVs) on protein function
is the disruption of post-translational modifications (Kim et al., 2015).
As phosphorylation is the most ubiquitous modification, the potential
for phosphorylation sites to be affected by amino acid variants is high.
For example, the PhosphoSitePlusr database (Hornbeck et al., 2015)
has identified numerous sequence variants that fall within the immediate
vicinity of a phosphorylation site, and the recent analysis of cancer driver
mutations has implicated phosphorylation as being a major factor in
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understanding the disruption of signalling pathways caused by amino acid
variations (Reimand et al., 2013).
There have been numerous examples of disease-associated naturally
occurring variants that impact the phosphorylation status of proteins.
The majority of such examples have involved a variant disrupting
a phosphorylation site in the reference protein, though there have
been at least two examples of missense mutations found to introduce
phosphorylation sites (Gentile et al., 2008; Lagarde et al., 2012). While
there have been relatively few studies experimentally determining the
effect of naturally occurring variants on phosphorylation, there are tens
of thousands of nsSNVs that have the potential to impact phosphorylation.
The PhosphoSitePlusr PTMVar dataset (Hornbeck et al., 2015) , which
is comprised of missense mutations cross-referenced to post-translational
modifications, contains over 19,000 examples of variants falling within
a 15-residue window surrounding a known phosphorylation site. Such
variants have the potential to disrupt existing phosphorylation sites, but
there will be many additional variants with the potential to introduce new
phosphorylation sites. The PTM-SNP database collates variants that occur
in the vicinity of a number of post-translational modifications, including
phosphorylation (Kim et al., 2015).
There have also been databases developed that catalogue the predicted
effect of SNVs on potential phosphorylation sites. Ryu and colleagues
defined the term “phosphovariant” to refer to a mutation that impacts the
phosphorylation status of an amino acid (Ryu et al., 2009). To predict
examples of phosphovariants, they developed PredPhospho, a support
vector machine model that predicts kinase-specific phosphorylation sites
based on the amino acid motifs surrounding potential phosphorylation
sites. Applying PredPhospho to missense mutations obtained from Swiss-
Prot, they predicted examples of phosphovariants and incorporated them
into the PhosphoVariant database (Ryu et al., 2009). The PhosSNP
database is another example of cataloging variants predicted to modify
protein phosphorylation (Ren et al., 2010). Ren and colleagues employed
the GPS 2.0 software, a kinase-specific phosphorylation site predictor
that uses optimised substitution matrices (Xue et al., 2008). The GPS 2.0
predictor was applied to variants from the dbSNP database (Sherry et al.,
2001), with the variants predicted to cause a change in phosphorylation
status or to cause a change in the kinase targeting the phosphorylation site
compiled into the PhosSNP database.
Most recently, the MIMP (mutation impact on phosphorylation)
method has been developed, which uses position weight matrices and
Gaussian mixture models to score the probability that a variant will cause
loss or gain of phosphorylation (Wagih et al., 2015). In contrast to the other
methods, MIMP provides a prediction service rather than a database. For
the purpose of consistency with the most recently published work, we will
consider two classes of “phosphovariants”: phosphorylation-loss causing
variants and phosphorylation-gain causing variants.
The current methods for predicting the effect of nsSNVs on
phosphorylation, described above, operate on the sequence content
surrounding a potential phosphorylation site. While methods based on
linear motifs can predict the potential for a kinase binding site to be
disrupted (Kobe andBodén, 2012), the presence of a valid kinase-substrate
binding motif on a protein is no guarantee that a kinase will come into
contact with the protein (Zhu et al., 2005). We have previously developed
a method, PhosphoPICK, for predicting kinase substrates using protein-
protein interaction networks and protein abundance across the cell cycle.
The use of such context information can improve the prediction accuracy
of kinase-specific phosphorylation site prediction from sequence by over
two-fold at low false-positive levels (Patrick et al., 2015). An approach that
integrates cellular context information with sequence information should
therefore be able to provide a more accurate assessment of the effect of
SNVs on phosphorylation than methods that operate on sequence alone.
Building on the properties of PhosphoPICK, we present here a method
for quantifying the effect of nsSNVs on protein phosphorylation status.
Taking stock of known missense mutations across the proteome, as
collected in UniProt, we use PhosphoPICK to build kinase-specific,
proteome-wide sets of predicted variant effects on phosphorylation. These
sets provide a “background distribution” that can be used to calculate a
measure of significance for the predicted effect that a novel variant has on
phosphorylation loss or gain.
In order to validate our approach, we searched the literature
for naturally occurring variants causing phosphorylation loss or gain,
identifying 24 such variants. By comparing the threshold at which
our method detects true positives against that of the background, we
demonstrate that our method is able to detect over 50% of the known
phosphovariants within the first 2% of the background distribution. We
further validate our method against three restricted sets of simulated
negatives based on structural and network features, and show that our
method maintains high prediction accuracy with an average AUC of
0.94 across all tests performed. These results demonstrate the method’s
reliability in detecting true examples of differential phosphorylation
from the vast number of potential phosphovariants. Applying the
method to variants in the vicinity of phosphorylation sites from the
PhosphoSitePlusr PTMVar dataset (Hornbeck et al., 2015), we find that
the predicted phosphovariants are over-represented among the ones with
disease annotations. These results support the conclusion that our method,
named PhosphoPICK-SNP, is able to detect variants that have functional
significance.
2 Methods
2.1 Data Resources
2.1.1 Missense mutation data
We obtained the UniProt index of protein altering variants (Consortium,
2015), which maps dbSNP variants (Sherry et al., 2001) to proteins within
the UniProt database (downloaded March, 2015). This file contained
752,857 variants mapped to amino acid variants in UniProt proteins. The
variants covered 89,909 protein sequences in the UniProt database.
2.1.2 Phosphorylation sites affected by naturally occurring variants
Through a manual search of the literature, we compiled a list of naturally
occurring variants that were found experimentally to either disrupt or
introduce a phosphorylation site. For the purpose of this work we
included variants that were shown either in vivo or in vitro to affect
the phosphorylation of a specific site, or the ability of a kinase to bind
to the site. Although there are examples of studies showing changing
phosphorylation levels on the protein, we only recorded examples where
the precise phosphorylation site was known. Table 1 contains the list of
identified genes, with variant and phosphorylation site affected. We found
21 examples of phosphorylation loss and 3 examples of phosphorylation
gain in response to nsSNVs. Of the 21 loss-causing variants, 6 of the
mutations are on the phosphorylation site. The total 24 variants are across
21 unique proteins.
2.2 Building background distributions of variant effects
We built distributions of predicted variant effects on phosphorylation in a
kinase-specific manner across all protein altering variants. PhosphoPICK
employs two Bayesian network models to make predictions. The first
model classifies kinase-substrate binding sites from sequence, and
incorporates position-specific amino acid frequencies and counts of co-
occurring neighbouring amino acids within some m length window
surrounding a potential phosphorylation site (Patrick et al., 2016). This
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model is henceforth referred to as the sequence model. Separately, a
Bayesian network model integrates the sequence model with protein-
protein interaction and association data sourced from BioGRID (Chatr-
aryamontri et al., 2015) and STRING (Franceschini et al., 2013), as well
as protein abundance data across the cell cycle (Olsen et al., 2010), in
order to calculate the probability that a kinase ordinarily targets a given
protein (Patrick et al., 2016). This model is henceforth referred to as the
combinedmodel.When scoring the effect of a variantweusePhosphoPICK
to generate three scores: (1)Rsubstrate, the prior probability based on the
combined model that the kinase would be expected to target the reference
protein, (2) Rsite the probability according to the sequence model that
the kinase will phosphorylate the site of interest on the reference protein,
and (3) Vsite the probability that the kinase will target the site of interest
on the variant protein.
Kinases within PhosphoPICK contain different optimal binding site
windows that are considered when making a prediction for a potential
phosphorylation site. Therefore, given a query kinase, we checked for
variants that fell within a window surrounding a potential phosphorylation
site. For each potential phosphorylation site, we recorded a reference
peptide and a variant peptide containing the missense mutation. We then
used the sequence model to obtain the Rsite and Vsite scores from the
reference and variant peptides respectively. If the central residue for a
peptide is not a valid phosphorylation site (for example a threonine is
mutated to an arginine) it will be scored 0. We defined a score difference,
Dsite = Vsite  Rsite (1)
where a negative value ofDsite indicates the variant is predicted to cause
decreased probability of phosphorylation, and a positive value represents
an increased probability of phosphorylation.
We calculated distributions of Dsite values in a kinase-specific
manner across all potential phosphorylation sites that contained a
missense mutation within the window for the query kinase. A potential
phosphorylation site is defined as any serine (S) or threonine (T) residue
for S/T kinases, any tyrosine (Y) residue for Y kinases, or any S/T/Y
residue for dual specificity kinases.
2.3 Calculating variant significance
The significance of the effect on phosphorylation by a variant is calculated
in a kinase-specific manner, as described by the following procedure.
Given some kinaseK, anm length window corresponding toK is centred
on potential phosphorylation siteswithin the protein sequence, where if the
variant falls within a window,m length reference and variant peptides are
retained.Dsite is then calculated from the reference and variant peptides
using Equation 1. The difference is then compared to the background
distribution and a P-value from both tails of the distribution is calculated
– representing whether the difference is greater (increased probability of
phosphorylation) or less (decreased probability of phosphorylation) than
would be expected by chance. The P-values are calculated such that
Ploss =
1
n
nX
i=1
I(Di  Dsite) (2)
Pgain =
1
n
nX
i=1
I(Di  Dsite) (3)
wheren is the number of variants contained in the background distribution
for kinase K and I() is the indicator function. The final P-value
representing the site, Psite, is calculated as the minimum of Ploss and
Pgain.
The Rsubstrate context score for the query protein is then retrieved.
As for the Dsite scores, we have distributions of context scores across
Table 1. Naturally occurring variants that have been shown through in
vivo or in vitro experiments to affect the phosphorylation status of the
proteins, by modifying the phosphorylateable residue or an adjacent
residue. The effect can be to disrupt an existing phosphorylation site
(loss), or introduce a new one (gain).
Gene Variant Phos. site Effect Reference
Cyclin D1 T286R T286 loss Benzeno et al. (2006)
hOG1 S326C S326 loss Luna et al. (2005)
TP53 P47S S46 loss Li et al. (2005)
TP53 R213Q S215 loss Wagih et al. (2015)
TP53 R282W T284 loss Wagih et al. (2015)
BDNF V66M T62 loss Deng et al. (2013)
CDKN1A D149G S146 loss Oh et al. (2007)
hERG1 K897T T897 gain Gentile et al. (2008)
PPAR2 P113Q S112 loss Ristow et al. (1998)
PTP-1B P387L S386 loss Echwald et al. (2002)
UBE3A T485A T485 loss Yi et al. (2015)
PER2 S662G S662 loss Toh et al. (2001)
MeCP2 R306C T308 loss Ebert et al. (2013)
NKX3-1 R52C S48 loss Gelmann et al. (2002)
PLN R14C S16 loss Ceholski et al. (2012)
ABCB4 T34M T34 loss Gautherot et al. (2014)
MAF P59H T58 loss Niceta et al. (2015)
GLUT1 R223W S226 loss Lee et al. (2015)
AR R405S S405 gain Lagarde et al. (2012)
Gab1 T387N T387 loss Ortiz-Padilla et al. (2013)
STAT1 L706S Y701 loss Dupuis et al. (2001)
CLIP1 E1012K S1009 loss Wagih et al. (2015)
CTNNB1 S37C S33 loss Wagih et al. (2015)
CTNNB1 G34R S47 gain Wagih et al. (2015)
the proteome for each kinase. We therefore calculate an empirical P-value
for theRsubstrate score, Psubstrate, based on a count of the proteome-
wide context scores that are greater than or equal to Rsubstrate, using
the same form as Equation 3. We then use Fisher’s method to combine
the two P-values into a combined P-value that represents the confidence
of the variant effect size given both the difference in sequence scores and
likelihood that the reference protein would ordinarily be a substrate of the
query kinase. Given the P-values Psite and Psubstrate, we calculate:
X =  2(ln(Psubstrate) + ln(Psite)) (4)
where X follows a Chi squared distribution with 4 degrees of freedom. The
combined P-value, Pcombined, can then be derived from X . As a single
phosphovariant can be scored with all kinases available to PhosphoPICK
(currently numbering 107), we correct the P-value for multiple testing
using a Bonferroni multiple correction on Psite and Pcombined to obtain
Esite and Ecombined.
2.4 Evaluating method accuracy on known variants
In order to calculate an estimate of the number of potential phosphorylation
sites that were affected by the presence of a nearby variation, we used a
10-fold cross-validation approach to build a set of predicted background
values. The proteinswithin the background set were split into 10 partitions,
where 9 of the partitions were used to construct distributions for both the
context scores and theDsite values. These distributions were then used to
evaluate and obtain E-values for the variants in the remaining partition. For
each variant the lowest E-value was retained as representing the greatest
likelihood that the mutation resulted in a change in phosphorylation status.
To evaluate our method on its ability to detect the examples of
differential phosphorylation recorded in Table 1, we evaluated the known
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Fig. 1. Line-curves showing the tradeoff between the percentage of positive differential phosphorylation examples identified and the number of variants considered (as the E-value cut-off
decreases). Comparison is made between predicting phosphorylation change using sequence alone, and combining sequence with context. Shown is the tradeoff until all positive examples
are detected (a), as well as the tradeoff up until 10% of the background variants are detected (b).
variants on our method using each of the 10 partitions from the cross-
validation test to construct the background distributions. For each variant
we calculated the median of the E-values generated across the cross-
validation runs; similar to the background, the final E-value assigned to
a variant was the minimum of the E-values for all potential kinases. Due
to the difficulty of defining a true negative set, we first compared to the
full background set the E-value thresholds at which the true positives were
identified; i.e. at each E-value threshold calculated for a true positive, we
calculated the number and percentage of variants in the background set
that were also identified at that threshold. We performed this test using
both Esite and Ecombined values to understand the influence of context
on predicting phosphorylation change.
We further evaluated our method on several sub-sets of the background
set, chosen to simulate negatives based on the following assumptions. The
primary assumption is that by defining criteria, based on structural or
network data, that preclude the occurrence of phosphorylation at a given
site, the occurrence of a variant will not alter the phosphorylation status
of the site. For the purpose of this work, we define three non mutually-
exclusive criteria: phosphorylation sites are less likely to occur (1) in
solvent inaccessible/buried regions of a protein; (2) in transmembrane
domains; (3) in proteins that do not interact either directly (first-order
interactions) or through mediators (second-order interactions) with a
kinase. Buried amino acids were predicted using the ACCpro 5 method
(Magnan andBaldi, 2014) from the SCRATCHprotein structure prediction
suite of programs (Cheng et al., 2005). Transmembrane domains were
predicted using TMHMM 2.0 (Krogh et al., 2001). Proteins that have no
first or second-order interactions with a kinase in our set were identified
based on a PPI network from BioGRID (Chatr-aryamontri et al., 2015).
We note that as our method includes BioGRID data in its predictions, this
could introduce a positive bias; however, as our method does not include
structural data, the first two setswill not exhibit such bias.Wegenerated the
three negative sets as follows. For the structural data, we first defined a 15-
residue window around a potential phosphovariant. For set 1, we defined
as negatives the potential phosphovariants whose 15-residue window fell
in a predicted buried region; i.e. all 15 amino acids were required to be
buried. For set 2, negatives were defined as potential phosphovariants with
the 15-residue window falling in a predicted transmembrane helix. Set 3
was constructed by taking potential phosphovariants that occur in proteins
with no first or second-order PPIs with a kinase in our set.
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Fig. 2. Histogram showing the distribution of combined E-value (Ecombined) scores
for the subset of 65,203 variants predicted to be phosphovariants based on sequence alone
(Esite < 0.05).
We compared our method’s ability to detect the known variants against
that of the MIMP predictor (Wagih et al., 2015). We downloaded the local
version of the software, and ran the background set of protein sequences
and variants through it, specifying cutoff probability and log values of 0
to enable a comparison over all thresholds.
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Fig. 3. Line-curves showing a comparison of detecting experimentally confirmed phosphovariants between the combined PhosphoPICK-SNP method and MIMP (Wagih et al., 2015).
Shown is the tradeoff until all positive examples are detected (a), as well as the tradeoff up until 10% of the background variants are detected (b).
3 Results
The experimentally determined examples of differential phosphorylation
listed in Table 1 were used to gauge how well our method performed
in identifying real examples of phosphorylation gain and loss. Figure 1
shows a tradeoff between the percentage of known positives detected and
the background at eachE-value threshold a positivewas discovered at, with
the values for each threshold recorded in Supplementary Table 1. When
predicting phosphovariants using the combined E-value, we found that the
majority (over 50%) of the known positives could be identified within the
first 2% of the background distribution. We were able to identify 75% of
the experimental examples at an E-value threshold corresponding to 11%
of the background. These results demonstrate that the method can identify
true positive examples of phosphovariants at high levels of specificity,
which represent candidates of real interest to biologists.
We also evaluated the use of sequence only for predicting
phosphovariants (i.e. using the Esite value), in order to determine if
the incorporation of context information was providing an increase in
prediction accuracy. When using sequence alone, the majority of variants
were not detected until 8% of the background distribution was reached
(Figure 1). Given the combined method detected the majority of variants
at 2% of the background, this represents a 4-fold increase when using the
combined E-value. As can be seen from Figure 1(a), at the more liberal
E-value thresholds there was less difference between sequence alone and
the combined E-values. However, these results show that the approach of
combining context and sequence information provides the greatest benefit
for identifying true variants at higher levels of specificity.
We next compared our method’s prediction accuracy for classifying
the positive phosphovariant examples against three simulated negative
sets. The negative sets were defined by the occurrence of a potential
phosphovariant in (1) a solvent inaccessible/buried region, (2) a
transmembrane helix and (3) a protein that has no first or second-order PPIs
with a kinase in our set. We evaluated prediction accuracy using area under
the receiver operating characteristic curve (AUC). Supplementary Table
2 shows AUC values for the various comparisons. We found prediction
accuracy as measured by AUC was high on the test-sets of simulated
negatives. The AUC for evaluating the predictions on PPI network-based
simulated negatives was 0.94 (with 216,630 negatives), 0.95 for buried
regions (35,312 negatives), and 0.95 for those based on transmembrane
domains (12,741 negatives). These values were consistently higher than
those of using sequence alone, with AUC values ranging from 0.86 to 0.87.
These high AUC values across multiple test sets demonstrate the ability
of our approach to distinguish true phosphovariants from high confidence
negatives.
3.1 Estimating phosphorylation sites affected by SNVs
In order to investigate the effect of context on predicting differential
phosphorylation, we used the methods for calculating Esite and
Ecombined to estimate the number of putative phosphorylation sites
affected by the nsSNVs contained in the UniProt index of protein
altering variants. We performed two tests: firstly, we identified predicted
differentially-phosphorylated sites on the basis of Esite, where if
Esite fell below 0.05 the variant was considered to cause differential
phosphorylation; i.e. a phosphovariant. In the second test, theEcombined
value was applied as a filter, where only variants with Ecombined and
Esite falling below 0.05 were classified as a phosphovariant.
Based on our cross-validated analysis of the background distribution,
we identified the variants that were predicted to be causing differential
phosphorylation. In total we found 65,203 variants that were predicted,
based on their Esite value, to cause differential phosphorylation. When
requiring that a variant obtain an E-value < 0.05 for both Esite and
Ecombined, the number dropped to 41,075. Figure 2 shows a histogram
of the Ecombined values calculated for all the variants that were found
to be significant based on Esite alone. While the majority maintain a
high level of significance when context is included, nearly 40% of the
variants obtained an E-value> 0.05 after context is included. These results
illustrate the effect that context has in filtering out spurious examples of
phosphovariants where the kinase is unlikely to target the query protein.
3.2 Comparison with alternative method
We compared the ability of the MIMP method (Wagih et al., 2015) to
predict the set of positives out of the background to our combined method.
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As MIMP was unable to make predictions for two of the phosphorylation
gain sites (due to the centre residue of the reference protein being non-
phosphorylatable) we performed the comparison using the remaining 21
phosphorylation loss-causing variants and 1 gain-causing variant. As can
be seen from Figure 3 (the individual comparison values are also recorded
in Supplementary Table 3), at stricter cut-off thresholds our method is
able to detect greater numbers of the true positive examples. Within 2%
of the background distribution our method is able to detect 55% of the
22 phosphovariants, however MIMP does not reach 55% until 4.9% of
the background – this corresponds approximately to an additional 31,000
variants. We also performed comparisons using our 3 sets of simulated
negatives.We found that our combinedmethod consistently out-performed
MIMP across the test sets, with an average AUC of 0.94 for our method
compared to 0.91 for MIMP (Supplementary Table 2).
3.3 Phosphorylation loss in disease
We used our method to determine whether the variants that were
most confidently predicted to result in a change in phosphorylation
status were over-represented among disease-associated variants. We used
the PTMVar database from PhosphoSitePlusr, which cross-references
post-translational modification information from PhosphoSitePlusr with
variant information from the UniProt human variation database. The
PTMVar database annotates sites with the classification ‘Disease’,
‘Polymorphism’ or ‘Unclassified’. Variants that were within the vicinity
of phosphorylation sites and were annotated with either ‘Disease’ or
‘Polymorphism’ were selected. We then counted the number of times
that a variant in each of these classes was predicted to be differentially
phosphorylated with a decreased probability of phosphorylation (i.e. it
obtained an Ecombined value< 0.05 in a test for decreased probability),
and counted the number of times the variants in both classes were not
predicted to be differentially down-phosphorylated.
Fisher’s exact test was used to determine the over-representation. We
found that variants annotated as disease-associated were significantly
over-represented among the variants predicted to result in down-
phosphorylation, with a P-value of 0.0002. This indicates that while
the presence of a variant in the vicinity of a phosphorylation does not
necessarily result in phosphorylation disruption, our method is able to
detect the disease-associated variants that will have a strong impact on
phosphorylation.
To further investigate our method’s ability to identify disease-relevant
examples of phosphorylation loss, we compared our predictions with a
set of 58 genes previously found to have significant levels of cancer-
associated mutations in phosphorylation site regions (Reimand and Bader,
2013). We found that 47 out of the 58 genes contained at least one
predicted phosphovariant, with anEcombined value under 0:05 in a test of
phosphorylation loss. A permutation analysis based on random sampling
of 58 proteins from our background set confirmed that finding 47 out of
58 proteins containing predicted phosphovariants is greater than would be
expected by chance (P = 1e 05). There was a total of 1025 predicted
phosphovariants distributed across the 47 proteins. A second permutation
test counting the number of predicted phosphovariants from randomly
sampled sets of 58 proteins showed that this number of phosphovariants
was also greater than expected by chance (P < 1e 100).
3.4 Prediction of phosphorylation disruption in
disease-associated sites
Given that ourmethod is reliably able to detect phosphorylation loss events,
we used it to identify the most likely examples of phosphorylation loss in
the PhosphoSitePlusr PTMVar database that were associated with at least
one of five cancer types: ovarian, breast, colorectal, liver and pancreatic.
These variants were run through our method, and variants that obtained
E-values below 0.05 for bothEsite andEcombined were retained. Table 2
lists top scoring variants with their disease associations, where the variant
has been mapped to the vicinity of a phosphorylation site. The full list
of variants is available in Supplementary Table 4. In total, we found 52
examples of predicted phosphorylation loss caused by variants related
to ovarian cancer, 12 for breast cancer, 8 for colorectal cancer, 19 for
liver cancer and 9 for pancreatic cancer. We found that the kinases most
frequently associated with the phosphovariants were DNAPK, CK2A1,
CaMK4 and GSK3B, which were each predicted to be targeting five of the
phosphovariants (Supplementary Table 5).
We found several examples of predicted phosphorylation loss on the
-catenin protein (Uniprot accession number P35222), which was a top
candidate for phosphorylation loss for both ovarian and liver cancer.
The T41 phosphorylation site, which has been previously identified as a
GSK3B target (van Noort et al., 2002), is a known site mutated in cancers
(Sagae et al., 1999). It is predicted by PhosphopICK-SNP that the T41A
mutation would abolish a GSK3B phosphorylation site at T41 (Table 2)
Therewas also an example of predicted phosphorylation loss on tumour
suppressor protein p53 (Uniprot accession number P04637), which has
been shown previously to lose phosphorylation as a consequence of a
P47S mutation (Li et al., 2005). The E271K variant, which was associated
with both pancreatic and colorectal cancer (Sjöblom et al., 2006), was
found to have a significant likelihood of disrupting the phosphorylation
site at S269. The phosphorylation site at S269 is known to be an important
regulator of p53 transcriptional activity (Wu et al., 2011).
4 Discussion
With increasing numbers of disease-associated variants being catalogued,
the need for reliable functional annotations is only going to continue to
grow. While there are many potential functional effects of gene-coding
variants on protein function (Hecht et al., 2013), including the perturbation
of protein stability (Pires et al., 2014) or the disruption of one of the
many post-translational modifications that proteins undergo (Kim et al.,
2015), phosphorylation is a high-probability target of disruption due to the
ubiquitous nature of this protein modification process (Hornbeck et al.,
2015). We have presented here a method for quantifying the expected
effect of nsSNVs on protein phosphorylation, and have demonstrated that
it detects experimentally confirmed examples of phosphovariants at high
levels of specificity.
An advantage of our approach is the consideration of the cellular
context that kinases and their substrates operate in. We have shown that
by incorporating context into the prediction of phosphovariants, we can
identify positive examples of phosphovariants at higher levels of specificity
than if using sequence alone. There are examples of phosphovariants that
represent a trivial loss of phosphorylation; the removal of a phosphorylated
serine, threonine or tyrosine residue will by definition cause loss of
phosphorylation. A method that operates only on sequence may be able
to correctly predict such cases, but introduce false-positive predictions
for cases where the mutation occurs on a residue adjacent to the
phosphorylation site. Given the small number of trivial losses contained
in our test set, the specificity increase gained by incorporating context into
predictions indicates that our method is able to predict a broader spectrum
of potential phosphovariants than by using sequence alone. In addition,
when comparing our method to an alternative method of predicting the
effect of variants on phosphorylation, MIMP, we found that we could
predict positive examples of phosphorylation loss at stricter specificity
levels than the MIMP method.
While there are over 19,000 examples of missense mutations in the
vicinity of a phosphorylation site according to the PhosphoSitePlusr
PTMVar dataset (Hornbeck et al., 2015), we found that the mutations
with the strongest propensity for causing phosphorylation loss were
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Table 2. Cancer-associated variants predicted to cause loss of phosphorylation. Variants are listed according to the cancer or disease they
are associated with. Each row contains protein name as UniProt accession, the location of the variant and phosphorylation site, the kinase
predicted to target the site, the reference and variant scores for the peptide. The five most significant (according toEcombined score) variants
for each cancer type are shown, while the full list of significant variants for each cancer is shown in Supplementary Table 4. Where a variant
is predicted to affect multiple kinases, or multiple phosphorylation sites, each prediction is listed separately.
Cancer type Protein Variant Phos. site Kinase Rsubst: Rsite Vsite Ecombined Peptide
Ovarian P35222 G555A T551 Akt2 1.0 1.0 4.95E-05 9.36E-09 QDTQRRTpSMG[G/A]TQ
P26010 Y753H Y753 FAK 1.0 1.0 0.0 2.23E-08 YRLSVEI[Yp/H]DRREYSR
Q7KZI7 S197N S197 NEK6 1.0 1.0 0.0 2.3E-07 KIADFGF[Sp/N]NEFTFGN
P51813 S212R S212 GSK3B 0.998 1 0 1.33e-07 PPSSST[Sp/R]LAQYDS
P46939 M1256R T1259 MARK2 1 0.914 0.0005 4.47e-05 R[M/R]KSTpEVLP
Breast P14859 S88F S88 DNAPK 1.0 1.0 0.0 8.6E-06 SQQPSQP[Sp/F]QQPSVQA
P43355 K278T Y276 Brk 0.998 1 0.000491 0.000103 RALAETSYpV[K/T]VLEYV
P03372 H6Y T2 VRK1 0.0492 0.0792 0.00421 0.00111 MTpMTL[H/Y]TKA
Q99490 D816Y S818 P38B 0.0186 0.587 0.000173 0.00126 CTPSG[D/Y]LSpPLSREPP
P54646 S523G S527 p90RSK 0.36 0.78 0.00501 0.00214 LTG[S/G]TLSSpVSPRLGS
Colorectal P04637 E271K S269 CAMK2A 1 0.781 0.011 0.000131 NLLGRNSpF[E/K]VRVC
Q9P253 A913S S912 ERK5 0.495 0.848 0.0394 0.00475 APPPAKGSp[A/S]RAKEAE
Q9NPD5 I292M S293 CaMK4 0.832 0.524 3.21e-08 0.00785 ERK[I/M]SpLSLH
Q6ZMN7 G784R S783 CaMK4 0.792 0.454 1.52e-06 0.00954 TQSSSp[G/R]QSS
Q92953 V450I S448 ROCK1 0.326 0.845 0.00479 0.012 RAKRNGSpI[V/I]SMNL
Liver P35222 T41A T41 GSK3A 1 1 0 2.28e-09 GIHSGAT[Tp/A]TAPSLSG
P35222 S37F S37 GSK3A 1 1 0 2.28e-09 YLDSGIH[Sp/F]GATTTAP
P35222 T41A T41 IKKA 1 1 0 7.97e-09 GIHSGAT[Tp/A]TAPSLSG
P35222 S37F S37 IKKA 1 1 0 7.97e-09 YLDSGIH[Sp/F]GATTTAP
P35222 T41A T41 GSK3B 1 0.997 0 8.13e-06 IHSGAT[Tp/A]TAPSLS
Pancreatic Q9BYV9 T519I T519 p70S6K 1 1 0 1.14e-08 LETRTR[Tp/I]SSSCSS
P04637 E271K S269 CAMK2A 1 0.781 0.011 0.000131 NLLGRNSpF[E/K]VRVC
Q9BYV9 T519I S525 p70S6K 1 0.84 0.0917 0.000294 [T/I]SSSCSSpYSYAED
P56715 A135V S137 MARK2 0.848 0.987 2.83e-06 0.000418 IS[A/V]HSpPPHP
P05129 P524R Y521 Brk 0.356 0.227 0.000117 0.000629 TFCGTPDYIA[P/R]EIIA
associated significantly with disease annotations. While computational
analysis of variants has predicted both phosphorylation loss and gain to be
associated with disease (Radivojac et al., 2008), this study represents an
analysis of the predicted effect of variants on experimentally determined
phosphorylation sites. However, a greater availability of experimentally
identified phosphorylation gain-causing variants would enable an analysis
on the link between phosphorylation gain and disease. There are at least
three experimentally identified examples of naturally occurring variants
causing a gain of phosphorylation (Table 1). In the human ERG1 (hERG1)
protein for example, a lysine to threoninemutation at position 897 (K897T)
introduces a phosphorylation site at the mutated residue (Gentile et al.,
2008). Similarly, amutation on the human androgen receptor gene, R405S,
induces a phosphorylation site on residue 405 (Lagarde et al., 2012).
There are key residues within a kinase-substrate binding motif that
determine the ability of a kinase to catalyse a phosphorylationmodification
(Brinkworth et al., 2003; Kobe et al., 2005). The mutation of these key
residues can disrupt the phosphorylation site, and specific effects will
depend on the associated kinase. For example, the loss of a proline at
the +1 position relative to a phosphorylation site in a proline-directed
kinase-substrate binding motif will cause loss of phosphorylation (Ristow
et al., 1998; Li et al., 2005; Niceta et al., 2015). However, the mutation
of alternative, non-key, residues within the motif would not be expected
to disrupt the phosphorylation site the same extent. As a result, it is to be
expected that many missense mutations, even if they are in the vicinity
of a phosphorylation site, will not cause a loss of phosphorylation. Our
results indicate that PhosphoPICK-SNP is able to detect the mutations
that do have an impact on phosphorylation, and therefore have a greater
likelihood of being associated with disease.
5 Availability
The PhosphoPICK-SNP web-service takes as input protein sequences
in Fasta format, and information defining the mutation occurring in
the proteins. This follows the format used for missense mutations in
Tables 1 and 2, for example S523G. Users choose which kinases
to make predictions for, and select an E-value threshold for returning
results; results that obtain both Esite and Ecombined values below the
threshold will be returned. The output is an interactive table of results
which details the context score provided to the protein (Rsubstrate),
the reference and variant scores (Rsite and Vsite) obtained from the
potential phosphorylation peptide, the Ecombined value and the peptide
itself. More comprehensive information regarding the variant is available
in a downloadable tab-delimited text file of the results. In addition, we
encourage researchers to inform us of phosphovariants that they publish.
The phosphovariants listed in Table 1 are available online (linked from the
PhosphoPICK-SNP web-site), and we plan to update this table with new
examples of phosphovariants.
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